Although decentralized clinical trial (DCT) models have been in use for quite some time, adoption was relatively slow until the COVID-19 pandemic changed the entire healthcare and life sciences industries. Some of the slow growth of DCT adoption can be attributed to the complexity of deploying highly regulated IoT initiatives to patients across the globe.
Drug-based interventional DCTs only experienced a 7% CAGR between 2014 and 2019, and that rate jumped to 77% between the second halves of 2019 and 2020, following the onset of the pandemic. While DCT adoption explodes, it’s critical for life sciences companies to understand how to successfully decentralize their traditional clinical trials with IoT for connected health.
Download the eBook, “Roadmap to Decentralized Clinical Trials” to learn: